
UNIQURE NV shares plummeted 40% on Tuesday after four-year data for its Huntington's disease gene therapy fell short of the goal to slow progression. The drop follows the Netherlands-based biotech's application for approval in the United States.
UniQure shares dropped after four-year data for its Huntington disease gene therapy missed statistical goals for slowing progression. The trial showed mixed results compared with a control group, raising questions about its pending US application.

UNIQURE NV shares plummeted 40% on Tuesday after four-year data for its Huntington's disease gene therapy fell short of the goal to slow progression. The drop follows the Netherlands-based biotech's application for approval in the United States.
Everything you use on the web — faster, and in your pocket.